Literature DB >> 30702162

AMPK signalling: Implications for podocyte biology in diabetic nephropathy.

Maria Szrejder1, Agnieszka Piwkowska1.   

Abstract

Diabetic nephropathy is a major long-term complication of diabetes mellitus and one of the most common causes of end-stage renal disease. Thickening of the glomerular basement membrane, glomerular cell hypertrophy and podocyte loss are among the main pathological changes that occur during diabetic nephropathy, resulting in proteinuria. Injury to podocytes, which are a crucial component of the glomerular filtration barrier, seems to play a key role in the development of diabetic nephropathy. Recent studies have suggested that dysregulation of AMP-activated kinase protein, which is an essential cellular energy sensor, may play a fundamental role in this process. The purpose of this review is to highlight the molecular mechanisms associated with AMP-activated protein kinase (AMPK) in podocytes that are involved in the pathogenesis of diabetic nephropathy.
© 2019 Société Française des Microscopies and Société de Biologie Cellulaire de France. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  AMP-activated protein kinase; Diabetic nephropathy; Glomerular filtration barrier; Podocyte

Mesh:

Substances:

Year:  2019        PMID: 30702162     DOI: 10.1111/boc.201800077

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  12 in total

1.  Renoprotective effects of vitamin D3 supplementation in a rat model of metabolic syndrome.

Authors:  Nehal S Wahba; Salah A Ghareib; Rasha H Abdel-Ghany; Mohamed Abdel-Aal; Amira E Alsemeh
Journal:  Eur J Nutr       Date:  2020-04-22       Impact factor: 5.614

Review 2.  Nutrient sensing, signaling transduction, and autophagy in podocyte injury: implications for kidney disease.

Authors:  Dongqing Zha; Xiaoyan Wu
Journal:  J Nephrol       Date:  2022-06-15       Impact factor: 3.902

3.  NUP160 knockdown inhibits the progression of diabetic nephropathy in vitro and in vivo.

Authors:  Jiayong Xie; Zhi Chen; Gang Yao; Ying Yuan; Wenjuan Yu; Qiang Zhu
Journal:  Regen Ther       Date:  2022-06-17       Impact factor: 3.651

4.  MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3.

Authors:  Li Wang; Hua Li
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

5.  Revealing active components, action targets and molecular mechanism of Gandi capsule for treating diabetic nephropathy based on network pharmacology strategy.

Authors:  Qiqiang Zhang; Qing Ye; Xiaohui Huang; Ajing Xu; Yan Liu; Jia Qi; Hai Zhang; Jian Zhang
Journal:  BMC Complement Med Ther       Date:  2020-11-23

6.  PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1α Signaling Pathway.

Authors:  Hengmei Zhu; Zhi Fang; Jiehui Chen; Yun Yang; Jiacheng Gan; Liang Luo; Xiaojiang Zhan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-25       Impact factor: 3.168

7.  Exogenous spermine attenuates diabetic kidney injury in rats by inhibiting AMPK/mTOR signaling pathway.

Authors:  Xinying Zhang; Li Zhang; Zhe Chen; Siwei Li; Bingbing Che; Ningning Wang; Junting Chen; Changqing Xu; Can Wei
Journal:  Int J Mol Med       Date:  2021-02-04       Impact factor: 4.101

8.  GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.

Authors:  Jian Lu; Pei Pei Chen; Jia Xiu Zhang; Xue Qi Li; Gui Hua Wang; Ben Yin Yuan; Si Jia Huang; Xiao Qi Liu; Ting Ting Jiang; Meng Ying Wang; Wen Tao Liu; Xiong Zhong Ruan; Bi Cheng Liu; Kun Ling Ma
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 9.  Therapeutic Screening of Herbal Remedies for the Management of Diabetes.

Authors:  Mahmoud Balbaa; Marwa El-Zeftawy; Shaymaa A Abdulmalek
Journal:  Molecules       Date:  2021-11-12       Impact factor: 4.411

10.  VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy.

Authors:  Carolina Lavoz; Raul R Rodrigues-Diez; Anita Plaza; Daniel Carpio; Jesús Egido; Marta Ruiz-Ortega; Sergio Mezzano
Journal:  J Clin Med       Date:  2020-01-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.